Host and Viral Factors Affecting the Decreased Immunogenicity of Sabin Type 3 Vaccine after Administration of Trivalent Oral Polio Vaccine to Rural Mayan Children

Factors affecting immunogenicity of the first 2 doses of oral poliovirus vaccine (OPV) among unimmunized Mayan infants were prospectively evaluated. The relative impact of multiple variables, including mass or routine vaccination, concurrent enteric bacterial (salmonella, shigella, and campylobacter...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of Infectious Diseases Vol. 175; no. 3; pp. 545 - 553
Main Authors Maldonado, Yvonne A., Peña-Cruz, Victor, de la Luz Sanchez, Maria, Logan, Linda, Blandón, Stewart, Cantwell, Michael F., Matsui, Suzanne M., Millan-Velasco, Francisco, Valdespino, Jose Luis, Sepulveda, Jaime
Format Journal Article Web Resource
LanguageEnglish
Published Chicago, IL The University of Chicago Press 01.03.1997
University of Chicago Press
Oxford University Press
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Factors affecting immunogenicity of the first 2 doses of oral poliovirus vaccine (OPV) among unimmunized Mayan infants were prospectively evaluated. The relative impact of multiple variables, including mass or routine vaccination, concurrent enteric bacterial (salmonella, shigella, and campylobacter) and viral (adenovirus 40/41, astrovirus, nonpolio enteroviruses, and rotavirus) infections, interference among Sabin vaccine viruses, and preexisting poliovirus antibodies were studied. Sera were available from 181 infants after 2 OPV doses. Seroresponses were 86% to Sabin type 1, 97% to Sabin type 2, and 61% to Sabin type 3 vaccines. Mass versus routine vaccination and preexisting poliovirus antibodies did not affect immunogenicity. By multiple logistic regression analysis, fecal shedding of homologous Sabin strains was associated with increased seroresponses to all Sabin types, especially to Sabin type 3. Decreased OPV immunogenicity was primarily attributable to interference of Sabin type 3 by Sabin type 2. OPV formulations with higher doses of Sabin type 3 could improve immunogenicity among infants in developing countries.
Bibliography:Current affiliations: Cancer Biology Department, Harvard School of Public Health, Boston (V.P-c.); Regional Hospital, San Cristobal de las Casas, Chiapas, Mexico (F.M.-V.); Instituto Naciona1de Salud Publica, Cuemavaca, Mexico (J.L.V., J.S.).
Reprints or correspondence: Dr. Yvonne A. Maldonado, Dept. of Pediatrics, Stanford University School of Medicine, Stanford, CA 94305.
ark:/67375/HXZ-W7V5NWP7-G
istex:31D963E336DA0E48E93543B9107F791192B40CA2
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ISSN:0022-1899
1537-6613
DOI:10.1093/infdis/175.3.545